Loading...
•
Jun 30, 2023
Fate Therapeutics Q2 2023 Earnings Report
Reported financial results and business updates for the second quarter of 2023.
Key Takeaways
Fate Therapeutics reported $0.9 million in revenue for Q2 2023 and ended the quarter with $385.2 million in cash, cash equivalents, and investments. The company is advancing its FT522, FT819, and FT576 programs and plans to submit an IND application for FT825/ONO-8250 in the second half of 2023.
Phase 1 study start-up is ongoing for FT522 ADR-armed, CD19-targeted CAR NK Cell Program for B-cell Lymphoma.
IND submission planned in 2H23 under ONO collaboration for FT825/ONO-8250, a HER2-targeted CAR T-cell Program.
Dose escalation is ongoing in Phase 1 studies of FT819 CD19-targeted 1XX CAR T-cell Program for B-cell Malignancies and of FT576 BCMA-targeted CAR NK Cell Program for Multiple Myeloma.
Ended 2Q23 with $385 million in cash, cash equivalents, and investments, supporting runway into 2H25.
Revenue by Segment
Forward Guidance
Fate Therapeutics is focused on advancing its iPSC-derived cellular immunotherapies and plans to submit an IND application for FT825/ONO-8250 in the second half of 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...